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Simple Summary: Early-stage and castration-sensitive prostate cancer (PCa) growth is solely medi-
ated by androgen signaling pathways. AR signaling inhibitors (ARSIs) have significantly improved
clinical outcomes among men with PCa. In the metastatic castration-resistant PCa, there is presence
of both androgen-dependent and androgen-independent cells driving the tumor growth. Despite the
use of ARSIs, disease progression ultimately occurs in all patients with PCa and is due to genetic al-
terations in ARs, resulting in the outgrowth of androgen-independent cells. The possible mechanisms
include development of AR splice variants of which AR-V7 is more common, AR point mutations,
and AR overexpression. In addition, restoration of downstream signaling through alternate pathways
can also lead to androgen-independent growth of PCa. Therapeutic strategies to overcome these
resistance mechanisms and establish predictive biomarkers are still in clinical trials. This review
article details the current evidence on clinically relevant driver mechanisms, relevant biomarkers,
and treatment modalities to overcome resistance.
Abstract: Understanding of the molecular mechanisms of prostate cancer has led to development
of therapeutic strategies targeting androgen receptor (AR). These androgen-receptor signaling in-
hibitors (ARSI) include androgen synthesis inhibitor-abiraterone and androgen receptor antagonists-
enzalutamide, apalutamide, and darolutamide. Although these medications provide significant
improvement in survival among men with prostate cancer, drug resistance develops in nearly all pa-
tients with time. This could be through androgen-dependent or androgen-independent mechanisms.
Even weaker signals and non-canonical steroid ligands can activate AR in the presence of truncated
AR-splice variants, AR overexpression, or activating mutations in AR. AR splice variant, AR-V7
is the most studied among these and is not targeted by available ARSIs. Non-androgen receptor
dependent resistance mechanisms are mediated by activation of an alternative signaling pathway
when AR is inhibited. DNA repair pathway, PI3K/AKT/mTOR pathway, BRAF-MAPK and Wnt
signaling pathway and activation by glucocorticoid receptors can restore downstream signaling in
prostate cancer by alternative proteins. Multiple clinical trials are underway exploring therapeutic
strategies to overcome these resistance mechanisms.
Keywords: prostate cancer; castrate-resistant growth; metastases; androgen receptor; glucocorticoid
receptor; cytokines; transmembrane receptors; cell signaling; pharmacological targeting; neuroen-
docrine differentiation; lineage plasticity; prostate cancer stem cells
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1. Introduction
Prostate cancer (PCa) is the second most common malignancy among men [1]. Based
on Surveillance, Epidemiology and End Results Program-9 data, the age-adjusted incidence
and mortality of PCa for the period 2009 to 2018 showed a downward trend [2]. This
drift could be due to a decrease in the utilization of routine prostate specific antigen
(PSA) screening and the development of effective therapeutic strategies which prolong
PCa survival.
Androgen Receptor (AR) plays a key role in the pathogenesis of PCa. AR is a ligand-
activated nuclear transcription factor that belongs to the steroid hormone receptor family.
As testosterone (produced by Leydig cells in the testes) or 5-alpha-dihydrotestosterone
(DHT) (converted from testosterone in prostate tissue by 5-alpha-reductase type I and
II) binds to AR, the receptor dimerizes and translocates into the nucleus to bind to the
androgen response element (ARE) [3]. The AR modulates the transcriptional activity
of genes involved in escaping apoptosis and inducing cellular proliferation. Thus, AR
signaling results in the growth of PCa. A critical level of androgens is needed to activate
the required number of ARs on androgen-sensitive PCa cells for cell proliferation, the
absence of which by utilizing androgen ablation will result in activation of programmed
cell death [4]. Hence, the therapeutic strategy of androgen deprivation therapy (ADT) is
rational and beneficial in PCa. Although early-stage PCa is mostly mediated by androgen-
dependent cancer cells, the metastatic castrate-resistant stage is heterogenous with the
presence of both androgen-dependent and androgen-independent cells. The development
of castration resistance is mainly due to the development of genetic alterations in the AR
resulting in the outgrowth of androgen-independent cells [5]. In addition to the stimulation
of AR by androgen produced from the adrenal gland and testis, intra-tumoral secretion
of enzymes involved in the synthesis of testosterone such as cytochrome P450 17-alpha
hydroxysteroid dehydrogenase (CYP17) support tumor survival and growth [6]. The
understanding of these molecular mechanisms has led to the development of newer drugs
that act by inhibiting the enzymes for androgen production or block ARs. The agents
include abiraterone which can cause selective and irreversible inhibition of CYP17 and
small molecule AR antagonists such as enzalutamide [7]. Although these androgen-receptor
signaling inhibitors (ARSI) have been shown to significantly alter the natural history of
castration-resistant PCa (CRPC), drug resistance develops in most patients with time. In
this article, we will discuss the drugs that target AR and the clinically relevant resistance
mechanisms as well as therapeutic strategies to overcome the resistance.
2. Therapeutic Strategies Targeted at Androgen Signaling
2.1. Androgen Synthesis Inhibitors
Abiraterone acetate is an androgen synthesis inhibitor derived from pregnenolone and
is an irreversible inhibitor of 17, 20-lyase and 17-alpha hydroxylase which are products of
the CYP17 gene. The drug inhibits the production of androgen in the testes, adrenal glands,
and tumor cells [8]. The agent requires steroid supplementation to overcome secondary
cortisol insufficiency and prevent overproduction of ACTH and mineralocorticoids [8].
The drug is currently approved by the US Food and Drug Administration (FDA) for
use in newly diagnosed metastatic castration-sensitive PCa (CSPC) and metastatic CRPC.
Clinical trials that led to FDA approval of individual drugs are shown in Table 1.
Table 1. Clinical trials that led to U.S. Food and Drug Administration approval of androgen receptor signaling inhibitors.









COU-AA-301 III Abiraterone +ADT Placebo + ADT 1195
mCRPC
post-docetaxel 15.8 vs. 10.9
0.65
(0.54–0.77) [9]
COU-AA-302 III Abiraterone +ADT Placebo + ADT 1088
Chemo-naïve
mCRPC 34.7 vs. 30.3
0.81
(0.70–0.93) [10]
LATITUDE III Abiraterone +ADT Placebo + ADT 1199
De novo
mCSPC 53.3 vs. 36.5
0.66
(0.51–0.76) [11]
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Table 1. Cont.









AFFIRM III Enzalutamide +ADT Placebo + ADT 1199
mCRPC
post-docetaxel 18.4 vs. 13.6
0.63
(0.53–0.75) [12]
PREVAIL III Enzalutamide +ADT Placebo + ADT 1717
Chemo-naïve
mCRPC 32.4 vs. 30.2
0.71
(0.60–0.84) [13]
PROSPER III Enzalutamide +ADT Placebo + ADT 933 nmCRPC 67 vs. 56.3
0.73
(0.61–0.89) [14]







SPARTAN III Apalutamide +ADT Placebo + ADT 1207 nMCRPC 73.9 vs. 59.9 0.78 (0.016) [16]
TITAN III Apalutamide +ADT Placebo + ADT 1052
Denovo
mCSPC NR vs. 52.2
0.65
(0.53–0.79) [17]





Abbreviations: CSPC—castration sensitive prostate cancer, mCRPC—metastatic castration resistant prostate cancer, nmCRPC—non-
metastatic castration resistant prostate cancer.
2.2. Androgen Receptor Antagonists
Androgen receptor antagonists (ARA) block the androgen binding site of AR and
inhibit the nuclear translocation of AR and subsequent association of AR with nuclear
DNA. This results in attenuation of coactivator mobilization leading to cellular apoptosis
and decreased prostate tumor volume. The first-generation ARAs including bicalutamide,
nilutamide, and flutamide do not completely block AR activity. Enzalutamide, apalutamide,
and darolutamide are the currently utilized second-generation ARAs and have no agonistic
activity on AR compared to first-generation ARAs. Enzalutamide and apalutamide have a
similar mechanism of action and side effect profile [19]. Darolutamide has lower blood–
brain barrier penetration and low binding affinity for gamma-aminobutyric acid type A
receptors which resulted in lower incidence of CNS side effects [20]. Clinical trials relevant
to each drug are detailed in Table 1.
Enzalutamide is currently approved in de novo mCSPC, non-metastatic CRPC, mCRPC
in chemo naïve patients, and mCRPC which progressed after chemotherapy. In addition to
overall survival benefit, the medication also improved health-related quality of life and
benefited patients above 75 years of age with mCRPC [21,22]. Apalutamide is approved in
de novo mCSPC and non-metastatic CRPC. Darolutamide has benefit in improving median
metastasis-free survival, overall survival (OS), time to symptomatic skeletal event, and
time to chemotherapy in non-metastatic CRPC [20]. Clinical trial in mCSPC is ongoing [23].
Since abiraterone and apalutamide act by different mechanisms, clinical trials are
evaluating whether the combination provides superior outcomes. Preliminary reports
from abiraterone plus apalutamide combination trial showed improved PSA response
while results from abiraterone plus enzalutamide trial showed no improvement in OS and
increased side effects [24,25].
In the phase IV Safety Study of Continued Enzalutamide Treatment In Prostate Cancer
Patients (PLATO) trial that evaluated 251 patients who were on abiraterone after progres-
sion on enzalutamide, the median time to PSA progression (mPSA-P) was 2.8 months,
median radiologic progression free survival (rPFS) was 5.7 months, and only 4 patients
had PSA decline ≥50% [26,27]. This was redemonstrated in the post hoc analysis of the
COU-AA-302 trial where abiraterone after progression on enzalutamide (n = 55) gave
mPSA-P of only 3.9 months and a PSA decline ≥50% was seen in 44% of the patients [10].
The cohort of patients who had enzalutamide after progression on abiraterone (n = 33)
had an mPSA-P of 2.8 months and a PSA decline ≥50% in 67% of patients. These studies
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emphasize the development of AR-mediated cross-resistance which limits the clinical
benefit for subsequent use of alternate ARSI.
3. Acquired Castration Resistance
Despite the efficacy of ARSI, secondary resistance to these agents develops in nearly
all the patients due to molecular changes from selective pressure on AR. The various
secondary resistance mechanisms are discussed below with an emphasis on mechanisms
that have potential therapeutic implications and are compiled in Table 2.
Table 2. AR-mediated androgen receptor signaling inhibitor resistance mechanisms and drugs with potential action.
Aberration Mechanism Treatments Potentially Resistant Drugs with Potential Action and ActiveClinical Trials
AR variants Lack of ligandbinding domain
AR-V7
Abiraterone, Enzalutamide,
Apalutamide, Darolutamide * [28,29]
Bipolar androgen therapy [30]
Taxane chemotherapy * [31]
TAS3681 [32]
EPI-7386 [33]
Miverbresib + enzalutamide [34,35]
ZEN-3694 + enzalutamide [36]











Bipolar androgen therapy pretreatment [30]
Adaptive abiraterone therapy [45]
Miverbresib + enzalutamide [34,35]










F876L, F877L, G684A, K631T, L595M,
Q920R, R630Q, T576A, T878A) [46,47]
Darolutamide (A587V) [48]
Darolutamide (F876L, F877L, W742L, T787A,
W741L, T878A, L702H, H875Y) [48]




* Clinical benefit/resistance proven in clinical trials.
3.1. AR Splice Variants
De novo absence of efficacy with ARSI occurs in approximately 5–10% of mCRPC
patients and progression ensues in nearly all the patients who initially respond to these
drugs. These failures can be partly attributed to AR variants [55–57]. Truncated AR splice
variants (AR-V) contain intact activating sites including the N-terminal domain (NTD) and
the DNA-binding domain but lack the ligand-binding domain (LBD) where ARAs bind and
abiraterone exerts its indirect effect [58]. Based on the type of splice variant, downstream
transcriptional activity or AR expression abundance may be affected [59].
Androgen receptor isoform splice variant 7 (AR-V7) is the most common variant
detected and is not targeted by available ARSIs [60]. AR-V7 is common in metastatic PCa
(75%) and is rare in early-stage disease (<1%), suggesting that the expression adaptively
increases in tumors exposed to ARSI. The PROPHECY trial evaluated baseline circulating
tumor cell (CTC) AR-V7 among 118 patients prior to initiation of enzalutamide or abi-
raterone and found that the presence of CTC AR-V7 is associated with shorter PFS and OS,
and only 0–11% of patients showed a PSA response compared to 26–28% in AR-V7 negative
patients based on the assay used [28,29]. Soft tissue responses were also limited at 0–6%
compared to 21–25% in patients without CTC AR-V7. Another larger study of 202 men
with mCRPC confirmed the shorter OS in patients with the presence of CTC AR-V7 [28].
Detecting these variants previously required serial biopsies but the use of widely
available and validated liquid biopsy has made testing more accessible. Treating physi-
cians should consider testing for AR-V7 in patients who experience disease progression
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after ARSI. This approach can guide further treatment with an alternative ARSI versus
chemotherapy. The presence of CTC AR-V7 is not associated with primary resistance to
taxane chemotherapy [31]. Taxanes may be more effective in these patients compared to
ARSI while in AR-V7 negative men, both chemotherapy and ARSI (abiraterone or enza-
lutamide) have comparable efficacy [28]. Combining agents targeted at suppressing or
degrading AR-V7 to increase sensitivity to enzalutamide is only in preclinical stages and
not implemented in clinical trials [61–63].
Although apalutamide and darolutamide target full-length AR with no effect on AR-
V7 activity, resistance is seen in AR-V7 expressing enzalutamide- and abiraterone-resistant
models. This effect could be mediated by concurrent AKR1C3 enzyme activation in these
models which converts weak androgens to the more potent products: testosterone and
DHT. AKR1C3 also stabilizes AR-V7 and full-length AR (AR-FL), which results in increased
c-MYC expression that in turn activates AR target genes [64,65]. Knockdown of AKR1C3
decreased AR-V7 and c-MYC expression and reversed the cross-resistance to all four agents.
Indomethacin is a potent inhibitor of AKR1C3 and is being evaluated as a combination
treatment with enzalutamide in mCRPC in a phase I/II trial [66].
TAS3681 is an oral AR antagonist with full length-AR and AR-V7 downregulatory
activity and was shown to have antitumor efficacy in enzalutamide-resistant models. The
open-label phase I trials among 56 patients refractory to abiraterone (14.2%), enzalutamide
(46.4%), or both (39.3%) showed PSA response lasting up to 16.3 months with a manageable
safety profile [32]. The expansion phase of the study to assess preliminary efficacy is
currently ongoing. It also reduced the expression of c-MYC, an androgen-independent
driver of disease progression. The AR-NTD targeting drug EPI-7386 blocks full-length
AR and AR-V7 signaling [33]. It is being studied in combination with enzalutamide in
men with mCRPC in a phase I trial while EPI-506, which acts by a similar mechanism,
did not show significant PSA responses. As a result, the trial was terminated, and the
results were attributed to poor pharmacokinetics and considerable pill burden affecting
compliance [65].
AR-V567es is another splice variant identified in xenografts after prolonged ADT ex-
posure and increased in enzalutamide-resistant PCa cells [37,38]. CTC ARV-567es was more
common than CTC AR-V7 (78% vs. 67%) among 54 patients including 42.6% who received
prior ARSI; 54% of patients expressed double positivity. Although taxane chemotherapy
improved median PFS in CTC ARV-567es+ patients, the result is thought to be mediated
predominately by concurrent CTC AR-V7+ [39].
3.2. Activating Mutations in AR
3.2.1. AR Point Mutations
Point mutations in the hinge region or the LBD, which result in reduced ligand
specificity and increased trans-activation, are commonly found in mCRPC [67]. CTC
DNA studies showed that mutations L702H, T878A, H875Y, W742C, and W743L are
the most prevalent mutations with a median of 6 alterations per patient [68]. In the
presence of certain mutations, even weaker signals and non-canonical steroid ligands can
activate AR [48,69]. H875Y and T878A mutations resulted in activation of the AR pathway
promiscuously by estrogens and progesterone while T877A, H875Y, L701H, and L702H
mutations resulted in activation by glucocorticoids [69].
Some mutations convert AR antagonists into potent agonists. CTC DNA studies in
mCRPC patients resistant to apalutamide or enzalutamide, as well as animal studies, have
demonstrated that the F877L mutation converts enzalutamide and apalutamide into ago-
nists [46,47]. F877L mostly co-occurs with the T878A alteration in the endogenous AR allele
of the LNCaP cell line upon prolonged exposure to enzalutamide [70]. While enzalutamide
is a weak partial agonist of AR-F877L, it becomes a strong partial agonist with double
mutant AR-F877L/T878A [49]. However, structurally diverse ARSIs such as abiraterone
and galeterone can completely antagonize AR-F877L, as well as the AR-F877L/T878A
mutants. F877L, L702H, and T878A mutations mediate abiraterone resistance [71]. In
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preclinical studies, darolutamide was able to retain antagonistic properties against many
clinically relevant AR mutations (F877L, W742L, T7878A) thought to confer resistance to
antiandrogen therapies [70]. In addition, darolutamide is a full antagonist to the W741L
and T877A mutations, which mediate bicalutamide resistance, and to F876L mutations,
which mediate enzalutamide and apalutamide resistance. In an in vitro study assessing
response of ARAs to 68 AR mutations in men with CRPC, darolutamide retained efficacy
in all gain-of-function AR-FL mutations except A587V [48]. In contrast, enzalutamide
caused full or partial activation of 8 mutant types. Nonetheless, it is unclear how this
in vitro advantage of darolutamide will translate into clinical context with multiple genetic
alterations present in a tumor, poor in vivo bioavailability of darolutamide, and other
studies showing cross-resistance to the drug by mechanisms involving AKR1C3/ARV-7
pathway [64]. Of interest, CTC DNA analysis showed that three patients treated with
apalutamide acquired F876L mutation on CTC DNA analysis, that was absent prior to
treatment. All of these patients had an elevated PSA, but nearly 50% of patients in the entire
study population had ≥50% PSA reduction [24]. The clinical relevance of the antagonist-
agonist switch mechanism has itself been questioned. If point mutations convert ARSI into
potent agonists, withdrawal of the agent should result in improvement in PSA and clinical
status. In a study of 47 patients whose disease progressed after enzalutamide treatment,
only 5 experienced anti-androgen withdrawal syndrome which was of short duration [72].
Hence, the co-existence of other alterations could impact the outcomes.
TRC253 is a high-affinity competitive binder of wild-type (WT) and mutant AR with
proven efficacy in F877L mutant mice models. The drug is currently being studied in a
phase I trial and is enrolling for the dose-expansion phase including patients with an F877L
mutation [50,51].
PROTACs are protein degrading agents, of which, ARV-110 is currently being evalu-
ated in a phase I/II trial in mCRPC. It degrades the AR in PCa cell lines and animal models
with high potency leading to lower expression of PSA [52,53]. This drug produces efficient
ubiquitination and degradation of AR by the proteasome and consequent apoptosis in
AR-dependent cells. AVR-110 also reduced AR-target gene expression in enzalutamide-
resistant tumor models, targeted wild type AR (WT-AR), and amplified AR with T878A,
H875Y, F877L, and M895V mutations, but not in tumors with L702H or AR-V7 mutations.
Interim results supported a further dose escalation with PSA reduction ≥50% in two out
of five patients with T877A and H874 mutations and 2 patients with wildtype AR [73].
ARCC-4 is another PROTAC, derived from enzalutamide, which was shown to degrade
AR in VCaP cell lines which exhibit resistance mechanisms including AR amplification,
AR-V7, F876L, W741L, M896V and T877A mutations [54].
3.2.2. AR Overexpression
Approximately 80% of patients with CRPC have marked increase in AR mRNA and
protein expression [74–77]. Increased AR expression through gene amplification is consid-
ered the mechanism responsible for progression with ADT in about 30% of the patients. AR
overexpression coexists with AR point mutations in about 18% of the patients [74,75,78–80].
Nearly 80% of the tumors with AR overexpression show elevated AR gene copy numbers
and 30% have high-level amplifications. AR gene amplification is more common in CRPC
compared to CSPC and has a poor impact on PFS and OS [7,81].
Although in most cases (92%), AR amplification in CTC DNA corresponds to amplifi-
cation in matched solid biopsy samples, exceptions do occur. A 10-fold AR amplification
was detected on CTC DNA analysis in a patient with bone and lymph node metastasis
while the same was not detected in a corresponding lymph node biopsy. It was postulated
that the tumor clones with high AR amplification were localized to sites of bony metasta-
sis [40]. AR amplification is also more common in patients that progressed on enzalutamide
compared to abiraterone or other agents (53% vs. 17% or 21%; p = 0.02) [41]. AR ampli-
fication is currently being evaluated as a predictive biomarker for low 177Lu-PSMA-617
activity [43]. Mechanistically, AR inhibition upregulates PSMA expression which leads to
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higher uptake of PSMA-ligand drugs such as 177 Lu-PSMA-617 and increased PSMA tracer
uptake on PET in patients with PCa. [82–87] In contrast, AR amplification downregulates
the PSMA-encoded FOLH1 gene expression, which reduces transcription of PSMA and
decreasing PSMA expression [88]. Patients with AR gain were 2.4 times less likely to have
a PSA response with PSMA-ligand therapy. Eighty percent of patients with AR gain had
early disease progression compared to 20% with normal AR copy levels. PFS was inferior
in patients with raised AR compared to normal AR (median 4.7 months vs. 9.4 months;
p = 0.020), and a similar pattern was seen with OS (median 7.4 vs. 19.1 months; p = 0.020).
Another study with 66 patients who received radioligand therapies (177Lu-PSMA-617,
177Lu-J591 and 225Ac-J591) showed that 47% had AR amplification or resistant mutations.
These patients were less likely to experience a PSA decline ≥30% compared to wild type; it
was also associated with inferior OS (median 12.4 vs. 21 months; p = 0.043) [44].
AR overexpression can also occur without gene amplification by stabilization of
the mRNA or protein or by increasing transcription rates [89–91]. This increase could
be mediated by the AR gene, expression of c-MYC, or other oncogenes [92–94]. AR
overexpression results in tumor growth despite minimal androgen stimulation [79,95].
In vitro models demonstrated conversion of bicalutamide to an AR agonist in presence of
this aberration [42]. On the other hand, episodic exposure to supraphysiologic doses of
testosterone can produce downregulation of AR and potential resensitization to ADT.
The phase II TRANSFORMER trial compared the efficacy of bipolar androgen therapy
(BAT) by cycling polar extremes of near-castrate and supraphysiologic testosterone levels
with enzalutamide in asymptomatic men with CRPC after progression on abiraterone.
Differences in PFS and OS were not statistically significant with either approach. However,
patients who underwent BAT followed by enzalutamide had better PFS2 compared to
enzalutamide followed by BAT (median 28.2 vs. 19.6 months, HR 0.44, 95%CI 0.22–0.88).
The OS was also superior in the BAT followed by enzalutamide group compared to the
enzalutamide alone group (median 37.1 vs. 28.6 months, HR 0.52, 95%CI 0.29–0.96). In this
study, 38% of the entire study population overexpressed AR and 9% had AR-V7 in CTCs.
These aberrations conferred numerically shorter PFS and OS on BAT and enzalutamide
therapies; however, the study was not powered to determine if these aberrations could
be used as treatment selection biomarkers [30]. It is possible that BAT can extend the
PFS on enzalutamide after progression with abiraterone; however, randomized controlled
trials are required to confirm this hypothesis. Another approach to eliminate selective
pressure on AR from continuous use of one ARSI is by adaptive therapy where patients are
switched between on- and off-cycles of treatment based on the PSA and tumor volume.
An interim analysis of adaptive abiraterone therapy among 15 patients with mCRPC
demonstrated a median rPFS of at least 30 months using only 49% of the conventional
continuous abiraterone therapy dose [45].
Bromodomain and extra-terminal chromatin readers (BET) inhibitors including miver-
bresib and ZEN-3694 regulate AR gene transcription to decrease AR expression and AR-V7
signaling, which results in tumor suppression [96]. Single agent use of miverbresib in a
phase I trial did not show a trend that was consistent with a clinical response; and hence,
trials with combination of BET inhibitor and enzalutamide are ongoing [34,35]. Phase
Ib/IIa results of combination ZEN-3694 plus enzalutamide in 75 patients who progressed
on abiraterone (40%), enzalutamide (45.3%), or both (11%) showed a median composite
radiographic and clinical PFS of 5.5 months with a 3.5-month mean duration of treatment
on the combination [36].
3.3. AR Crosstalk with OTHER Signal Transduction Pathways
Resistance to AR-targeted agents in PCa can also be mediated by activation of alter-
nate signaling pathways that are induced by peptide growth factors, PI3K/AKT/mTOR
pathway, glucocorticoid receptor (GR) pathway, and through restoration of downstream
signaling by alternative proteins.
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DNA repair pathway: Patients with tumor cells harboring pathogenic or likely
pathogenic variants of BRCA1 or BRCA2 benefit from PARP inhibitors such as olaparib or
rucaparib. Although data is limited, these agents can also be used with other homologous
recombinant repair (HRR) gene defects such as ATM, BARD1, BRIP1, CDK12, CHEK1,
CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L [97]. PARP-mediated
repair pathways are upregulated upon AR inhibition by bicalutamide and enzalutamide
and act as a mechanism for PCa cell survival. This process occurs due to ARA-induced
unresolved DNA damage, and the pathway could be effectively downregulated by the
addition of PARP-inhibitors [98]. In addition to sensitizing PCa cells to DNA damage,
PARP-inhibitors also sensitize them to androgen depletion [99]. Olaparib was combined
with abiraterone in a phase II trial among 142 patients with mCRPC after progression on
prior docetaxel. Approximately 15% of the patients had CTC DNA HRR gene defects.
The combination treatment significantly improved rPFS (median 13.8 vs. 8.2 months,
HR 0.65, 95%CI 0.44–0.97). As expected, grade 3 and 4 adverse events were common
among the combination therapy group (54% vs. 28%) [100]. A phase II trial evaluating
the efficacy of abiraterone with veliparib vs. abiraterone with placebo irrespective of HRR
gene defect status showed no significant difference in PSA response (72% vs. 64%) or PFS
(median 11 vs. 10.1 months). Of note, the patients whose tumors harbored a defective
HRR gene (27%) had higher radiology response rates (88% vs. 38%) and PSA response
rates (90% vs. 56%) compared to those without HRR defects [101]. Other ongoing trials
evaluating the potential benefits of combined therapy include PROPEL (olaparib with abi-
raterone), MAGNITUDE (niraparib with abiraterone), and TALAPRO-2 trials (talazoparib
with enzalutamide) [102–104].
PI3K/AKT/mTOR pathway: The PI3K/AKT/mTOR pathway is commonly altered
in PCa and signaling can be activated by enzalutamide through stabilization of AKT phos-
phatase [105–107]. Loss of function or deletion of the tumor suppressor was found in
approximately 60% of the CRPC patients while mutations that activate PIK3CA muta-
tions occurred in around 30% [108,109]. In preclinical models with PTEN loss, AR and
PI3K/AKT pathways maintained tumor survival by reciprocal feedback leading to enzalu-
tamide and abiraterone resistance. Dual inhibition of both the pathways is more effective
than blocking either of them [108,109]. A phase III trial with 1101 patients used an AKT
inhibitor, iptasertib. Those who were randomized to ipatesertib-abiraterone or ipatesertib-
placebo showed that median rPFS was significantly improved in patients with tumors
showing PTEN-loss by immunohistochemistry (n = 521, median 19.1 vs. 14.2 months, HR
0.65, 95%CI 0.45–0.95) or PIK3CA/AKT1/PTEN-alterations by next generation sequencing
(n = 205, median 19.3 vs. 14.1 months, HR 0.63, 95%CI 0.44–0.88) [110]. Another AKT-
inhibitor, capivasertib, combined with enzalutamide in patients who previously received
ARSI showed a positive response in 3 of the 15 patients. All three had PTEN loss or activat-
ing AKT mutations [111,112]. Other chemotherapies have been investigated in mCRPC
setting: PI3K inhibitor sonolisib (PX-866), AKT/mTOR inhibitor GSK2141795 and combina-
tion therapies with PX-866 plus abiraterone, and PI3K inhibitor BKM120 plus enzalutamide.
However, none of these studies resulted in meaningful clinical outcomes [113–115]. In
these combination trials, as well as with the use of the mTOR inhibitor everolimus and
the dual mTOR inhibitor MLN0128, the rapid rise in PSA was reversed when treatment
was discontinued, which, further confirms a crosstalk between multiple signaling path-
ways [6,116,117]. Samotolisib, a dual PI3K/mTOR inhibitor plus enzalutamide in a phase
Ib/II trial among men with mCRPC showed statistically significant improvement in me-
dian serological and radiographic PFS compared to enzalutamide alone (median 2.9 vs.
3.7 months, HR 0.66, 95%CI 0.43–0.99) [118]. GSK2636771, a selective PI3Kβ inhibitor in
a phase I/II trial, demonstrated a durable response in 3 of the 12 mCRPC patients, all, of
whom had tumors harboring PIK3CB mutations [119].
BRAF-MAPK pathway: Alternative signaling through the MAPK pathway was identi-
fied as a potential growth pathway in 2 patients with enzalutamide resistant PCa harboring
a BRAF-K601E mutation [120,121]. Pharmacologic inhibition of BRAF or downstream
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components of MAPK pathway along with AR inhibition resulted in significant inhibition
of cell proliferation. With 90% of metastatic PCa harboring alterations in MAPK pathway,
larger studies may help us understand if this synergism is reproducible in the clinical
setting [122]. BRAF mutations, on the other hand, occur in only about 2% of PCa patients.
CXCR7, an atypical chemokine receptor, is one of the most upregulated genes in enza-
lutamide resistant PCa cells. CXCR7 is repressed by AR but expression increased upon
ADT initiation, leading to activation of MAPK/ERK signaling [123]. MAPK inhibitors
were able to block CXCR7 downstream pathways, however, resistance developed rapidly.
Similarly, increased ERK1/2 expression was seen in tissue samples of men with CRPC.
ERK is the immediate downstream target of MEK1/2, and trametinib, a MEK inhibitor,
elicited biochemical and clinical responses in a heavily pretreated mCRPC patient [124].
AR-tropomyosin receptor kinase (TRK) crosstalk mediated through nerve growth factor
(NGF) also promoted tumor growth in ARSI challenged PCa cell lines, and are targetable by
NTRK1/TRKA inhibitors [125]. However, the clinical utility of these inhibitors is limited
as NTRK mutations are rarely detected in prostate cancer [126].
Wnt signaling pathway: PCa cells can also gain the ability to synthesize and secrete
specific ligands and receptors that help sustain survival through the wnt-beta-catenin path-
way independent of androgen signaling [127]. A study among 137 mCRPC patients who
developed resistance to enzalutamide or abiraterone found that 11% developed activating
mutations in CTNNB1, APC, or RNF43, which are involved in wnt-beta catenin pathway,
and that these mutations conferred shorter OS. Interestingly, the CTNNB1 mutations were
found only in enzalutamide treated patients. Beta-catenin signaling causes downstream up-
regulation of hypoxia inducible factor-1 alpha (HIF1α) and vascular endothelial growth fac-
tor (VEGF), which promotes angiogenesis. However, targeting mCRPC by tyrosine kinase
inhibitors as a monotherapy has not resulted in any clinically beneficial outcomes [111,112].
Though, the HIF1α inhibitor NLG207 in combination with enzalutamide and CCS1477
(inhibitor of the HIFα-AR coactivator CBP-p300) is being evaluated for suppressing the
AR-HIFα pathway in patients previously treated with enzalutamide [128–130].
Glucocorticoid receptor (GR) activation: Enzalutamide resistance has been attributed
in some cases to increased GR expression, which can drive transcription of AR-related
genes [131,132]. GR expression was found in only 30% of CSPC but, expression increased
after ADT [133]. Of note, AR and GR share the same chromatin binding sites and GR
can regulate genes in the AR-pathway [134]. Interestingly, mechanistic studies showed
that resistance to enzalutamide can be mediated by increased GR (or other nuclear steroid
receptor expression) after exposure to the drug [131]. By overcoming the ligand deficiency
conferred by ADT, and regulating AR target genes, the GR-bypass model is a potential
resistance mechanism. Loss of TLE3, a transcriptional corepressor, leads to increased GR
expression and is implicated in apalutamide and enzalutamide resistance [131]. However,
the phase I/II open-label trial of enzalutamide combined with mifepristone, a GR antag-
onist, in patients with mCRPC showed no benefit in delaying time to PSA-P compared
to enzalutamide alone (HR = 1.34, p = 0.395) [135,136]. Another phase I/II trial that as-
sessed a selective GR antagonist, CORT125281, plus enzalutamide in mCRPC patients
whose cancer progressed on abiraterone is ongoing [137]. In patients who developed
progressive disease on abiraterone-prednisone, switching the steroid from prednisone to
dexamethasone resulted in PSA decline ≥50% in 34.6% of patients with a median rPFS
of 11.8 months [138]. The lower equivalent GR and mineralocorticoid receptor activity of
dexamethasone compared to prednisone is postulated as a possible mechanism. Patients
with AR gain detected in plasma CTC, however, did not respond to the switch.
Neuroendocrine differentiation: Treatment-related neuroendocrine differentiation
is quite prevalent in mCRPC. Studies showed that 16.9% of patients who had disease
progression after ADT demonstrated small cell histology on biopsies of metastases [139].
Development of small cell PCa confers a poor prognosis with an OS of 36.6 months
compared to 44.5 months in patients with adenocarcinoma (HR 2.02, 95%CI 1.07–3.82). TP53
and RB1 loss can occur as adaptative mechanisms to selective pressures on AR and result
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in AR independence in the tissue. Overexpression of n-myc and cell-cycle kinase Aurora
kinase-A, which drive AR-independent progression by lineage plasticity, was identified in
metastatic neuroendocrine PCa [140]. A phase II trial of Alisertib, an inhibitor of ARORA
kinase-A and n-myc, in neuroendocrine PCa included 34% of patients who progressed on
prior ARSI therapy. Although exceptional responders were identified among patients with
genomic amplification of MYCN and AURKA; overall, the study did not meet the primary
end-points of 6-month PFS (13.4%) or OS benefit (9.5 months). Inhibition of epigenetic
modifiers such as EZH2 were evaluated for their ability to potentially restore sensitivity to
ARSIs. Tazemetostat, an EZH2 inhibitor currently used in epithelioid sarcoma and follicular
lymphoma, and CPI-1205 are being evaluated in phase I/II trials [23,141]. A phase I trial
of a combination of CPI-1205 plus cobicistat (a CYP3A4 blocker) with enzalutamide (after
progression on abiraterone) or abiraterone (after progression on enzalutamide) Showed a
PSA decline of ≥80% in 14.7% of patients. This PSA decline was mainly confined to the
AR-V7 negative group. The phase II part of the trial comparing CPI-1205 with or without
enzalutamide has begun.
PD-1/PDL-1 immunoinhibitory pathway: Higher expression of PDL-1 in patients
with enzalutamide-resistant PCa prompted the phase III IMbassador250 trial that combined
enzalutamide with the PDL-1 blocker atezolizumab in mCRPC after progression on abi-
raterone or chemotherapy [142]. However, the trial was discontinued due to high toxicity
and no improvement in OS [143]. Another trial evaluating a combination of enzalutamide
with pembrolizumab in untreated mCRPC patients is ongoing [144].
4. Conclusions
Significant advantages have been made in the management of CRPC with second-
generation androgen receptor antagonists and androgen synthesis inhibitors. However,
the benefits are often short-lived due to the rapid development of resistance to these
drugs. Extensive studies on the resistance mechanisms have opened the way to new
drug developments which are aimed at reducing the emergence of resistant clones as
well as targeting them. These drugs are still in the pipeline with clinical utility being
evaluated in numerous clinical trials. Although preclinical data have been promising,
many agents were not clinically beneficial. This result is possible because of the interaction
of multiple crosstalk pathways and genetic aberrations occurring concurrently, which
makes targeted monotherapies less effective. Further understanding of the nuances of
resistance mechanisms and wider utilization of clinical trials can help in development of
these agents.
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